Cryoport Inc
CYRX9.690USD
+0.190+2.00%
Close 11/25, 16:00（ET）Quotes delayed by 15 min
485.17MMarket Cap
8.14P/E TTM
More Details of Cryoport Inc Company
Cryoport, Inc. is engaged in supply chain solutions for cell and gene therapies. The Company’s supply chain solutions enable manufacturers, contract manufacturers (CDMO’s), contract research organizations (CRO’s), developers, and researchers to carry out their business with certainty. The Company provides a broad array of supply chain solutions for the life sciences industry. Through its platform of critical products and solutions, including advanced temperature-controlled packaging, informatics, specialized bio-logistics services, bio-storage, bio-services, and cryogenic systems, the Company is enabling the future of medicine worldwide, through its systems, compliant procedures, and approach to supply chain management. Its products and services include Cryoport Express Shippers, Cryoport ELITE Shipper Systems, Cryoport Consulting Services, Cryoport Bioservices, CRYOGENE, CRYOPDP Temperature-controlled Logistics, Cryoport Cryoshuttle, IntegriCell Services, Tec4Med, and others.
Cryoport Inc Info
Ticker SymbolCYRX
Company nameCryoport Inc
IPO dateJul 24, 2015
CEOMr. Jerrell Wilson (Jerry) Shelton
Number of employees1090
Security typeOrdinary Share
Fiscal year-endJul 24
Address112 Westwood Place, Suite 350
CityBRENTWOOD
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code37027
Phone19492321900
Websitehttps://www.cryoport.com/
Ticker SymbolCYRX
IPO dateJul 24, 2015
CEOMr. Jerrell Wilson (Jerry) Shelton
Company Executives of Cryoport Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jerrell Wilson (Jerry) Shelton
Mr. Jerrell Wilson (Jerry) Shelton
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.00M
+2.56%
Mr. Daniel M. (Dan) Hancock
Mr. Daniel M. (Dan) Hancock
Independent Director
Independent Director
45.86K
+102.52%
Ms. Linda Baddour
Ms. Linda Baddour
Independent Director
Independent Director
44.90K
+107.03%
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Independent Director
Independent Director
38.43K
+186.15%
Mr. Mark Sawicki
Mr. Mark Sawicki
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Dr. Ramkumar Mandalam, Ph.D.
Dr. Ramkumar Mandalam, Ph.D.
Independent Director
Independent Director
--
--
Mr. Robert S. Stefanovich
Mr. Robert S. Stefanovich
Chief Financial Officer, Senior Vice President, Chief Administrative Officer
Chief Financial Officer, Senior Vice President, Chief Administrative Officer
--
--
Mr. Ram M. Jagannath
Mr. Ram M. Jagannath
Independent Director
Independent Director
--
--
Mr. Scott Eckstein
Mr. Scott Eckstein
Investor Relations
Investor Relations
--
--
Mr. Edward J. Zecchini
Mr. Edward J. Zecchini
Senior Vice President, Chief Digital and Technology Officer
Senior Vice President, Chief Digital and Technology Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Jerrell Wilson (Jerry) Shelton
Mr. Jerrell Wilson (Jerry) Shelton
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
1.00M
+2.56%
Mr. Daniel M. (Dan) Hancock
Mr. Daniel M. (Dan) Hancock
Independent Director
Independent Director
45.86K
+102.52%
Ms. Linda Baddour
Ms. Linda Baddour
Independent Director
Independent Director
44.90K
+107.03%
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Dr. Robert J. (Bob) Hariri, M.D., Ph.D.
Independent Director
Independent Director
38.43K
+186.15%
Mr. Mark Sawicki
Mr. Mark Sawicki
Senior Vice President, Chief Scientific Officer
Senior Vice President, Chief Scientific Officer
--
--
Dr. Ramkumar Mandalam, Ph.D.
Dr. Ramkumar Mandalam, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Life Science products
21.09M
46.39%
BioLogistics solutions
19.87M
43.72%
BioStorage/Bioservices
4.50M
9.89%
By RegionUSD
Name
Revenue
Proportion
Americas
33.24M
73.12%
Asia Pacific
6.38M
14.04%
Europe & Middle East & Africa (EMEA)
5.83M
12.83%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Life Science products
21.09M
46.39%
BioLogistics solutions
19.87M
43.72%
BioStorage/Bioservices
4.50M
9.89%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Cadian Capital Management LP
9.95%
Morgan Stanley & Co. LLC
9.11%
BlackRock Institutional Trust Company, N.A.
6.74%
The Vanguard Group, Inc.
5.71%
Brown Capital Management, LLC
5.24%
Other
63.25%
Shareholders
Shareholders
Proportion
Cadian Capital Management LP
9.95%
Morgan Stanley & Co. LLC
9.11%
BlackRock Institutional Trust Company, N.A.
6.74%
The Vanguard Group, Inc.
5.71%
Brown Capital Management, LLC
5.24%
Other
63.25%
Shareholder Types
Shareholders
Proportion
Investment Advisor
42.52%
Investment Advisor/Hedge Fund
25.29%
Hedge Fund
22.33%
Research Firm
11.05%
Individual Investor
4.01%
Bank and Trust
0.67%
Sovereign Wealth Fund
0.43%
Pension Fund
0.42%
Family Office
0.10%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
368
48.89M
97.65%
-8.69M
2025Q2
394
50.37M
100.47%
-14.50M
2025Q1
409
50.98M
101.73%
-14.79M
2024Q4
407
51.87M
104.93%
-14.28M
2024Q3
422
52.00M
105.24%
-13.61M
2024Q2
423
53.55M
108.72%
-9.95M
2024Q1
437
55.31M
112.51%
-7.56M
2023Q4
468
54.03M
110.37%
-6.18M
2023Q3
482
49.41M
101.04%
-7.52M
2023Q2
492
49.81M
109.19%
-5.40M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Cadian Capital Management LP
4.97M
9.93%
-12.80K
-0.26%
Jun 30, 2025
Morgan Stanley & Co. LLC
4.55M
9.08%
-60.87K
-1.32%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
3.41M
6.8%
+151.66K
+4.66%
Jun 30, 2025
The Vanguard Group, Inc.
2.79M
5.57%
+43.03K
+1.57%
Jun 30, 2025
Brown Capital Management, LLC
3.80M
7.59%
-254.65K
-6.28%
Jun 30, 2025
Millennium Management LLC
2.56M
5.12%
+350.15K
+15.83%
Sep 24, 2025
Fred Alger Management, LLC
2.36M
4.71%
-173.42K
-6.85%
Jun 30, 2025
Thematics Asset Management SAS
1.66M
3.32%
+1.04M
+168.96%
Mar 31, 2025
Natixis Investment Managers SA
1.91M
3.82%
+216.94K
+12.78%
Jun 30, 2025
Assenagon Asset Management S.A.
1.50M
2.99%
+408.26K
+37.44%
Sep 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
Invesco NASDAQ Future Gen 200 ETF
0.52%
Inspire Small/Mid Cap ESG ETF
0.24%
JPMorgan Fundamental Data Science Small Core ETF
0.1%
Avantis US Small Cap Equity ETF
0.05%
Vanguard US Momentum Factor ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.04%
Global X Russell 2000 ETF
0.02%
ProShares UltraPro Russell2000
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.02%
ProShares Hedge Replication ETF
0.02%
View more
Invesco NASDAQ Future Gen 200 ETF
Proportion0.52%
Inspire Small/Mid Cap ESG ETF
Proportion0.24%
JPMorgan Fundamental Data Science Small Core ETF
Proportion0.1%
Avantis US Small Cap Equity ETF
Proportion0.05%
Vanguard US Momentum Factor ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.04%
Global X Russell 2000 ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.02%
ProShares Hedge Replication ETF
Proportion0.02%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Cryoport Inc?
The top five shareholders of Cryoport Inc are:
Cadian Capital Management LP holds 4.97M shares, accounting for 9.93% of the total shares.
Morgan Stanley & Co. LLC holds 4.55M shares, accounting for 9.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.41M shares, accounting for 6.80% of the total shares.
The Vanguard Group, Inc. holds 2.79M shares, accounting for 5.57% of the total shares.
Brown Capital Management, LLC holds 3.80M shares, accounting for 7.59% of the total shares.
Cadian Capital Management LP holds 4.97M shares, accounting for 9.93% of the total shares.
Morgan Stanley & Co. LLC holds 4.55M shares, accounting for 9.08% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 3.41M shares, accounting for 6.80% of the total shares.
The Vanguard Group, Inc. holds 2.79M shares, accounting for 5.57% of the total shares.
Brown Capital Management, LLC holds 3.80M shares, accounting for 7.59% of the total shares.
What are the top three shareholder types of Cryoport Inc?
The top three shareholder types of Cryoport Inc are:
Cadian Capital Management LP
Morgan Stanley & Co. LLC
BlackRock Institutional Trust Company, N.A.
Cadian Capital Management LP
Morgan Stanley & Co. LLC
BlackRock Institutional Trust Company, N.A.
How many institutions hold shares of Cryoport Inc (CYRX)?
As of 2025Q3, 368 institutions hold shares of Cryoport Inc, with a combined market value of approximately 48.89M, accounting for 97.65% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -2.82%.
What is the biggest source of revenue for Cryoport Inc?
In FY2025Q2, the Life Science products business generated the highest revenue for Cryoport Inc, amounting to 21.09M and accounting for 46.39% of total revenue.
